Abouchedid Rachelle, Hudson Simon, Thurtle Natalie, Yamamoto Takahiro, Ho James H, Bailey George, Wood Michelle, Sadones Nele, Stove Christophe P, Dines Alison, Archer John R H, Wood David M, Dargan Paul I
a Clinical Toxicology , Guy's and St Thomas' NHS Foundation Trust , London , UK.
b Laboratory and Managed Services , LGC Ltd , Fordham , Cambridgeshire, UK.
Clin Toxicol (Phila). 2017 Jun;55(5):338-345. doi: 10.1080/15563650.2017.1287373. Epub 2017 Feb 20.
Synthetic cannabinoid receptor agonists are the largest group of new psychoactive substances reported in the last decade; in this study we investigated how commonly these drugs are found in patients presenting to the Emergency Department with acute recreational drug toxicity.
We conducted an observational cohort study enrolling consecutive adult patients presenting to an Emergency Department (ED) in London (UK) January-July 2015 (6 months) with acute recreational drug toxicity. Residual serum obtained from a serum sample taken as part of routine clinical care was analyzed using high-resolution accurate mass-spectrometry with liquid-chromatography (HRAM-LCMSMS). Minimum clinical data were obtained from ED medical records.
18 (10%) of the 179 patient samples were positive for synthetic cannabinoid receptor agonists. The most common was 5F AKB-48 (13 samples, concentration 50-7600 pg/ml), followed by 5F PB-22 (7, 30-400 pg/mL), MDMB-CHMICA (7, 80-8000 pg/mL), AB-CHMINACA (3, 50-1800 pg/mL), Cumyl 5F-PINACA (1, 800 pg/mL) and BB-22 (1, 60 pg/mL). Only 9/18 (50%) in whom synthetic cannabinoid receptor agonists were detected self-reported synthetic cannabinoid receptor agonist use. The most common clinical features were seizures and agitation, both recorded in four (22%) individuals. Fourteen patients (78%) were discharged from the ED, one of the four admitted to hospital was admitted to critical care.
Synthetic cannabinoid receptor agonists were found in 10% of this cohort with acute recreational drug toxicity but self-reported in only half of these. This suggests that presentations to the ED with acute synthetic cannabinoid receptor agonist toxicity may be more common than reported.
合成大麻素受体激动剂是过去十年中报告的新型精神活性物质中数量最多的一类;在本研究中,我们调查了在因急性娱乐性药物中毒到急诊科就诊的患者中,这些药物的常见程度。
我们进行了一项观察性队列研究,纳入了2015年1月至7月(6个月)期间连续到英国伦敦一家急诊科就诊且有急性娱乐性药物中毒的成年患者。使用液相色谱高分辨率精确质谱法(HRAM-LCMSMS)分析作为常规临床护理一部分采集的血清样本中的残留血清。从急诊科病历中获取最少的临床数据。
179份患者样本中有18份(10%)合成大麻素受体激动剂检测呈阳性。最常见的是5F AKB-48(13份样本,浓度为50 - 7600 pg/ml),其次是5F PB-22(7份,30 - 400 pg/mL)、MDMB-CHMICA(7份,80 - 8000 pg/mL)、AB-CHMINACA(3份,50 - 1800 pg/mL)、Cumyl 5F-PINACA(1份,800 pg/mL)和BB-22(1份,60 pg/mL)。在检测出合成大麻素受体激动剂的18人中,只有9人(50%)自述使用过合成大麻素受体激动剂。最常见的临床特征是癫痫发作和躁动,各有4人(22%)出现。14名患者(78%)从急诊科出院,4名入院患者中有1人入住重症监护病房。
在该急性娱乐性药物中毒队列中,10%的患者被检测出含有合成大麻素受体激动剂,但只有一半患者自述使用过。这表明因急性合成大麻素受体激动剂中毒到急诊科就诊的情况可能比报告的更为常见。